Skip to main content

FOLFOX Plus Ramucirumab Fails to Improve PFS in Gastric, Esophageal Cancer

However, the anti-VEGFR2 monoclonal antibody was found to improve disease control rate, and to provide a longer progression-free survival in a subgroup of patients with gastric or gastroesophageal junction adenocarcinoma.
http://www.cancernetwork.com/asco-2014-gastrointestinal-cancer/folfox-plus-ramucirumab-fails-improve-pfs-gastric-esophageal-cancer
 

Disclaimer: This information is for educational purposes only, It is not to diagnose or treat your disease. If you do use the information contained on this web site without the approval of a health professional, you are prescribing for yourself, which is your constitutional right, but the author(s) and webmaster assume no responsibility

© 2022 Esophageal Cancer Education Foundation- by domino